The sustained upward trajectory of the Costochondritis market is fundamentally propelled by the rising prevalence of predisposing factors and associated medical conditions. A critical driver is the increasing incidence of inflammatory diseases globally, including rheumatoid arthritis and ankylosing spondylitis, which can trigger costochondral joint inflammation. Furthermore, the escalating rates of trauma to the chest wall, often resulting from automobile accidents and sports-related injuries, directly contribute to the patient pool experiencing costochondritis. The primary driver remains the pervasive issue of non-cardiac chest pain; with costochondritis accounting for a significant percentage of emergency room visits for chest pain, the necessity to rule out life-threatening cardiac events dramatically increases diagnostic expenditure, thereby fueling the Costochondritis market growth. Lifestyle and occupational factors also play a crucial role, as repetitive minor trauma from strenuous physical activities, such as heavy lifting and intense exercise, predisposes a larger segment of the population, particularly athletes and physically demanding jobholders, to this condition. The increasing patient awareness and improved diagnostic methods, including advanced imaging to confirm diagnosis by exclusion, further contribute to market expansion, ensuring more cases are correctly identified and treated.